These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34175973)

  • 41. Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate.
    Algahtani H; Shirah B; Marghalani S; Algarni A
    Mult Scler Relat Disord; 2019 Feb; 28():155-158. PubMed ID: 30597324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dimethyl fumarate for multiple sclerosis.
    Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
    Popova EV; Boyko AN; Orlova EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
    Bernardini LR; Zecca C; Clerici VT; Gobbi C; Mantegazza R; Rossi S
    J Neurol Sci; 2016 Oct; 369():139-140. PubMed ID: 27653880
    [No Abstract]   [Full Text] [Related]  

  • 46. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
    Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
    Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
    Lee CH; Jiang B; Nakhaei-Nejad M; Barilla D; Blevins G; Giuliani F
    Mult Scler Relat Disord; 2021 Jul; 52():103003. PubMed ID: 34118574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dimethyl fumarate induced migrating polyarthralgias.
    Villedon de Naide M; Moisset X; Soubrier M
    Joint Bone Spine; 2019 May; 86(3):399-400. PubMed ID: 30081200
    [No Abstract]   [Full Text] [Related]  

  • 49. Persisting lymphopenia and dimethyl fumarate: A clinical commentary.
    Diem L; Chan A
    Mult Scler; 2021 Jul; 27(8):1309-1310. PubMed ID: 33620267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
    Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Avasarala J; Jain S; Urrea-Mendoza E
    J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
    [No Abstract]   [Full Text] [Related]  

  • 53. NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis.
    Boulicault D; Duddy M
    Neurodegener Dis Manag; 2015; 5(1):7-10. PubMed ID: 25711449
    [No Abstract]   [Full Text] [Related]  

  • 54. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ; Carroll CA
    Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Blair HA
    Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
    Mirabella M; Prosperini L; Lucchini M; Boffa L; Borriello G; Buscarinu MC; Centonze D; Cortese A; De Fino C; De Giglio L; Elia G; Fantozzi R; Ferraro E; Francia A; Galgani S; Gasperini C; Haggiag S; Landi D; Marfia GA; Millefiorini E; Monteleone F; Nociti V; Salvetti M; Sgarlata E; Pozzilli C
    CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Harmel P; Schlunk F; Harms L
    Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors associated with dimethyl fumarate-induced lymphopenia.
    Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
    J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
    Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
    Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.